{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:08:07Z","timestamp":1788984487817,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-025-05068-7","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T21:36:33Z","timestamp":1749850593000},"page":"180-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["PSMA-RADS 2.0: a revised framework for PSMA-targeted imaging interpretation and clinical decision-making"],"prefix":"10.1007","volume":"51","author":[{"given":"Arwa","family":"Elsamny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Wardeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Panyukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Kandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refky","family":"Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"5068_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","volume":"73","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA (2018) PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA\u2013targeted PET Imaging Studies. Eur Urol 73:485\u2013487. https:\/\/doi.org\/10.1016\/j.eururo.2017.10.027","journal-title":"Eur Urol"},{"key":"5068_CR2","doi-asserted-by":"publisher","unstructured":"Leung KH, Rowe SP, Leal JP, et al (2022) Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET. EJNMMI Res 12:. https:\/\/doi.org\/10.1186\/S13550-022-00948-1.","DOI":"10.1186\/S13550-022-00948-1"},{"key":"5068_CR3","unstructured":"Prostate Cancer \u2014 Cancer Stat Facts. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed 16 May 2025"},{"key":"5068_CR4","doi-asserted-by":"publisher","first-page":"101438","DOI":"10.1016\/J.TRANON.2022.101438","volume":"22","author":"H Song","year":"2022","unstructured":"Song H, Guja KE, Iagaru A (2022) PSMA theragnostics for metastatic castration resistant prostate cancer. Transl Oncol 22:101438. https:\/\/doi.org\/10.1016\/J.TRANON.2022.101438","journal-title":"Transl Oncol"},{"key":"5068_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/J.EURURO.2020.09.041","volume":"79","author":"MB Cook","year":"2021","unstructured":"Cook MB, Hurwitz LM, Geczik AM, Butler EN (2021) An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment. Eur Urol 79:33\u201341. https:\/\/doi.org\/10.1016\/J.EURURO.2020.09.041","journal-title":"Eur Urol"},{"key":"5068_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2967\/JNUMED.118.215434","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert R, Telli T, Opitz M, et al (2023) Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine 64:738\u2013743. https:\/\/doi.org\/10.2967\/JNUMED.118.215434","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/S41391-021-00356-X","volume":"24","author":"DN Patel","year":"2021","unstructured":"Patel DN, Karsh LI, Daskivich TJ (2021) Next-generation imaging in localized high-risk prostate cancer. Prostate Cancer Prostatic Dis 24:585\u2013586. https:\/\/doi.org\/10.1038\/S41391-021-00356-X,","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5068_CR8","unstructured":"Chang SS (2004) (2004) Overview of prostate-specific membrane antigen. Rev Urol 6(Suppl 10) 13\u201318"},{"key":"5068_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40644-020-00300-7\/FIGURES\/25","volume":"20","author":"F De Galiza Barbosa","year":"2020","unstructured":"De Galiza Barbosa F, Queiroz MA, Nunes RF, et al (2020) Nonprostatic diseases on PSMA PET imaging: A spectrum of benign and malignant findings. Cancer Imaging 20:1\u201323. https:\/\/doi.org\/10.1186\/S40644-020-00300-7\/FIGURES\/25","journal-title":"Cancer Imaging"},{"key":"5068_CR10","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2967\/JNUMED.117.190215","volume":"58","author":"MM Osman","year":"2017","unstructured":"Osman MM, Iravani A, Hicks RJ, Hofman MS (2017) Detection of Synchronous Primary Malignancies with 68Ga-Labeled Prostate-Specific Membrane Antigen PET\/CT in Patients with Prostate Cancer: Frequency in 764 Patients. Journal of Nuclear Medicine 58:1938\u20131942. https:\/\/doi.org\/10.2967\/JNUMED.117.190215","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/ERC-18-0226","volume":"26","author":"MK Bakht","year":"2019","unstructured":"Bakht MK, Derecichei I, Li Y, et al (2019) Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer 26:131\u2013146. https:\/\/doi.org\/10.1530\/ERC-18-0226","journal-title":"Endocr Relat Cancer"},{"key":"5068_CR12","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/S00259-021-05245-Y\/TABLES\/4","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, et al (2021) E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging 48:1626\u20131638. https:\/\/doi.org\/10.1007\/S00259-021-05245-Y\/TABLES\/4","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5068_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2023.06.008","author":"RA Werner","year":"2023","unstructured":"Werner RA, Hartrampf PE, Fendler WP, et al (2023) Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 84:491\u2013502. https:\/\/doi.org\/10.1016\/J.EURURO.2023.06.008"},{"key":"5068_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/J.EURURO.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, et al (2023) Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 83:405\u2013412. https:\/\/doi.org\/10.1016\/J.EURURO.2023.02.002","journal-title":"Eur Urol"},{"key":"5068_CR15","doi-asserted-by":"publisher","unstructured":"Rafiei Alavi N, Rahmani M, Gupta A, Yaghmai V (2024) PSMA-RADS to improve evaluation and management of prostate cancer. Abdominal Radiology 1\u201312. https:\/\/doi.org\/10.1007\/S00261-024-04738-2\/METRICS","DOI":"10.1007\/S00261-024-04738-2\/METRICS"},{"key":"5068_CR16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/S11307-023-01841-6","volume":"25","author":"X Meng","year":"2023","unstructured":"Meng X, Ma W, Zhang J, et al (2023) PI-RADS-Based Segmented Threshold of PSMA-PET SUVmax Is Better than Traditional Fixed Threshold for Diagnosing Clinically Significant Prostate Cancer Especially for PI-RADS 3 Lesions. Mol Imaging Biol 25:887\u2013896. https:\/\/doi.org\/10.1007\/S11307-023-01841-6,","journal-title":"Mol Imaging Biol"},{"key":"5068_CR17","doi-asserted-by":"publisher","first-page":"8396","DOI":"10.7150\/THNO.58140","volume":"11","author":"J Jiao","year":"2021","unstructured":"Jiao J, Kang F, Zhang J, et al (2021) Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET\/CT: A real-world study. Theranostics 11:8396\u20138411. https:\/\/doi.org\/10.7150\/THNO.58140,","journal-title":"Theranostics"},{"key":"5068_CR18","doi-asserted-by":"publisher","unstructured":"Koerber SA, Boesch J, Kratochwil C, et al (2021) Predicting the risk of metastases by psma-pet\/ct\u2014evaluation of 335 men with treatment-na\u00efve prostate carcinoma. Cancers (Basel) 13:. https:\/\/doi.org\/10.3390\/CANCERS13071508,","DOI":"10.3390\/CANCERS13071508"},{"key":"5068_CR19","unstructured":"Factors predicting metastatic disease in 68Ga-PSMA-11 PET positive osseous lesions in prostate cancer. https:\/\/www.urotoday.com\/recent-abstracts\/urologic-oncology\/prostate-cancer\/120809-factors-predicting-metastatic-disease-in-68ga-psma-11-pet-positive-osseous-lesions-in-prostate-cancer.html?utm_source=chatgpt.com. Accessed 31 May 2025"},{"key":"5068_CR20","doi-asserted-by":"publisher","unstructured":"Yadav D, Dutruel SP, O\u2019Dwyer E, et al (2024) PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer. Eur J Radiol 180:. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111711","DOI":"10.1016\/j.ejrad.2024.111711"},{"key":"5068_CR21","doi-asserted-by":"publisher","first-page":"585213","DOI":"10.3389\/FONC.2020.585213\/BIBTEX","volume":"10","author":"X Zhou","year":"2021","unstructured":"Zhou X, Li YC, Jiang X, et al (2021) Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET\/CT in the Evaluation of Patients With Prostate Cancer. Front Oncol 10:585213. https:\/\/doi.org\/10.3389\/FONC.2020.585213\/BIBTEX","journal-title":"Front Oncol"},{"key":"5068_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/J.EUCR.2019.01.007","volume":"23","author":"DK Reyes","year":"2019","unstructured":"Reyes DK, Demehri S, Werner RA, et al (2019) PSMA-targeted [18F]DCFPyL PET\/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. Urol Case Rep 23:72\u201374. https:\/\/doi.org\/10.1016\/J.EUCR.2019.01.007","journal-title":"Urol Case Rep"},{"key":"5068_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/RLU.0000000000004524","volume":"48","author":"RA Bundschuh","year":"2023","unstructured":"Bundschuh RA, L\u00fctje S, Bundschuh L, et al (2023) High Interobserver Agreement on PSMA PET\/CT Even in the Absence of Clinical Data. Clin Nucl Med 48:207\u2013212. https:\/\/doi.org\/10.1097\/RLU.0000000000004524,","journal-title":"Clin Nucl Med"},{"key":"5068_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13550-020-00745-8\/FIGURES\/3","volume":"11","author":"J Kuten","year":"2021","unstructured":"Kuten J, Dekalo S, Mintz I, et al (2021) The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. EJNMMI Res 11:1\u20138. https:\/\/doi.org\/10.1186\/S13550-020-00745-8\/FIGURES\/3","journal-title":"EJNMMI Res"},{"key":"5068_CR25","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2967\/JNUMED.118.217588","volume":"59","author":"RA Werner","year":"2018","unstructured":"Werner RA, Bundschuh RA, Bundschuh L, et al (2018) Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET\/CT Imaging. Journal of Nuclear Medicine 59:1857\u20131864. https:\/\/doi.org\/10.2967\/JNUMED.118.217588","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR26","doi-asserted-by":"publisher","first-page":"E529","DOI":"10.1097\/RLU.0000000000004259","volume":"47","author":"A Letang","year":"2022","unstructured":"Letang A, Cromb\u00e9 A, Rousseau C, et al (2022) Bone Uptake in Prostate Cancer Patients: Diagnostic Performances of PSMA-RADS v1.0, Clinical, Biological, and 68Ga-PSMA-11 PET Features to Predict Metastasis after Biochemical Recurrence. Clin Nucl Med 47:E529\u2013E539. https:\/\/doi.org\/10.1097\/RLU.0000000000004259","journal-title":"Clin Nucl Med"},{"key":"5068_CR27","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2967\/JNUMED.119.241174","volume":"61","author":"LW Chiu","year":"2020","unstructured":"Chiu LW, Lawhn-Heath C, Behr SC, et al (2020) Factors Predicting Metastatic Disease in 68Ga-PSMA-11 PET\u2013Positive Osseous Lesions in Prostate Cancer. Journal of Nuclear Medicine 61:1779\u20131785. https:\/\/doi.org\/10.2967\/JNUMED.119.241174","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2967\/JNUMED.119.232504","volume":"61","author":"A Toriihara","year":"2020","unstructured":"Toriihara A, Nobashi T, Baratto L, et al (2020) Comparison of 3 Interpretation Criteria for 68Ga-PSMA11 PET Based on Inter- and Intrareader Agreement. Journal of Nuclear Medicine 61:533\u2013539. https:\/\/doi.org\/10.2967\/JNUMED.119.232504","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2967\/JNUMED.118.217653","volume":"60","author":"Y Yin","year":"2019","unstructured":"Yin Y, Werner RA, Higuchi T, et al (2019) Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories. Journal of Nuclear Medicine 60:511\u2013516. https:\/\/doi.org\/10.2967\/JNUMED.118.217653","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13550-020-0596-4\/FIGURES\/4","volume":"10","author":"C Derwael","year":"2020","unstructured":"Derwael C, Lavergne O, Lovinfosse P, et al (2020) Interobserver agreement of [68Ga]Ga-PSMA-11 PET\/CT images interpretation in men with newly diagnosed prostate cancer. EJNMMI Res 10:1\u201310. https:\/\/doi.org\/10.1186\/S13550-020-0596-4\/FIGURES\/4","journal-title":"EJNMMI Res"},{"key":"5068_CR31","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2967\/JNUMED.121.263159","volume":"62","author":"J Calais","year":"2021","unstructured":"Calais J, Czernin J (2021) PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy. Journal of Nuclear Medicine 62:1489\u20131491. https:\/\/doi.org\/10.2967\/JNUMED.121.263159","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR32","doi-asserted-by":"publisher","unstructured":"Khatri W, Chung HW, Werner RA, et al (2021) Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer. Diagnostics 2021, Vol 11, Page 665 11:665. https:\/\/doi.org\/10.3390\/DIAGNOSTICS11040665","DOI":"10.3390\/DIAGNOSTICS11040665"},{"key":"5068_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/RLU.0000000000004524","volume":"48","author":"RA Bundschuh","year":"2023","unstructured":"Bundschuh RA, L\u00fctje S, Bundschuh L, et al (2023) High Interobserver Agreement on PSMA PET\/CT Even in the Absence of Clinical Data. Clin Nucl Med 48:207\u2013212. https:\/\/doi.org\/10.1097\/RLU.0000000000004524","journal-title":"Clin Nucl Med"},{"key":"5068_CR34","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/S00330-023-10083-7\/FIGURES\/3","volume":"34","author":"F Grawe","year":"2024","unstructured":"Grawe F, Blom F, Winkelmann M, et al (2024) Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET\/CT scans in prostate cancer patients. Eur Radiol 34:1157\u20131166. https:\/\/doi.org\/10.1007\/S00330-023-10083-7\/FIGURES\/3","journal-title":"Eur Radiol"},{"key":"5068_CR35","doi-asserted-by":"publisher","DOI":"10.1148\/RYCAN.240390\/ASSET\/IMAGES\/LARGE\/RYCAN.240390.FIG4.JPEG","author":"YE Almalki","year":"2025","unstructured":"Almalki YE, Basha MAA, Ali SA, et al (2025) Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment. Radiol Imaging Cancer 7:e240390. https:\/\/doi.org\/10.1148\/RYCAN.240390\/ASSET\/IMAGES\/LARGE\/RYCAN.240390.FIG4.JPEG"},{"key":"5068_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/JNUMED.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, et al (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. Journal of Nuclear Medicine 59:469\u2013478. https:\/\/doi.org\/10.2967\/JNUMED.117.198119,","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR37","doi-asserted-by":"publisher","unstructured":"Kleiburg F, de Geus-Oei LF, Luelmo SAC, et al (2024) PSMA PET\/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients. Eur J Radiol 181:. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111774","DOI":"10.1016\/j.ejrad.2024.111774"},{"key":"5068_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S43055-022-00857-2\/TABLES\/6","volume":"53","author":"KA Kucuker","year":"2022","unstructured":"Kucuker KA, Yapar Z, Guney IB, Paydas S (2022) Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET\/CT. Egyptian Journal of Radiology and Nuclear Medicine 53:1\u201310. https:\/\/doi.org\/10.1186\/S43055-022-00857-2\/TABLES\/6","journal-title":"Egyptian Journal of Radiology and Nuclear Medicine"},{"key":"5068_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/S00259-020-04934-4\/TABLES\/1","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S, Goffin K, Hadaschik BA, et al (2021) Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 48:469\u2013476. https:\/\/doi.org\/10.1007\/S00259-020-04934-4\/TABLES\/1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5068_CR40","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2967\/JNUMED.121.263072","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, et al (2022) Novel Framework for Treatment Response Evaluation Using PSMA PET\/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. Journal of Nuclear Medicine 63:1651\u20131658. https:\/\/doi.org\/10.2967\/JNUMED.121.263072","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR41","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2967\/JNUMED.119.233817","volume":"61","author":"S Fanti","year":"2020","unstructured":"Fanti S, Hadaschik B, Herrmann K (2020) Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET\/CT Imaging: The PSMA PET Progression Criteria. Journal of Nuclear Medicine 61:678\u2013682. https:\/\/doi.org\/10.2967\/JNUMED.119.233817","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR42","doi-asserted-by":"publisher","first-page":"e0239414","DOI":"10.1371\/JOURNAL.PONE.0239414","volume":"15","author":"D Meijer","year":"2020","unstructured":"Meijer D, Jansen BHE, Wondergem M, et al (2020) Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. PLoS One 15:e0239414. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0239414","journal-title":"PLoS One"},{"key":"5068_CR43","doi-asserted-by":"publisher","unstructured":"Oyen RH, Van Poppel HP, Ameye FE, et al (1994) Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. https:\/\/doi.org\/101148\/radiology19028284375 190:315\u2013322. https:\/\/doi.org\/10.1148\/RADIOLOGY.190.2.8284375","DOI":"10.1148\/RADIOLOGY.190.2.8284375"},{"key":"5068_CR44","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/JNUMED.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, et al (2021) Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. Journal of Nuclear Medicine 62:596\u2013604. https:\/\/doi.org\/10.2967\/JNUMED.120.257238","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR45","unstructured":"ESMO 2023: Usefulness and Limitations of PSMA Imaging\/PET in High-Risk Localized Disease. https:\/\/www.urotoday.com\/conference-highlights\/esmo-2023\/esmo-2023-prostate-cancer\/147614-esmo-2023-usefulness-and-limitations-of-psma-imaging-pet-in-high-risk-localized-disease.html. Accessed 18 May 2025"},{"key":"5068_CR46","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.3390\/CANCERS15102787\/S1","volume":"15","author":"E Novruzov","year":"2023","unstructured":"Novruzov E, Schmitt D, Mattes-Gy\u00f6rgy K, et al (2023) Intra-Individual Comparison of Physiologic [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis. Cancers (Basel) 15:2787. https:\/\/doi.org\/10.3390\/CANCERS15102787\/S1","journal-title":"Cancers (Basel)"},{"key":"5068_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/S13550-024-01097-3","volume":"14","author":"CE Popescu","year":"2024","unstructured":"Popescu CE, Zhang B, Sartoretti T, et al (2024) Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET\/CT with an inter- and intrapatient based analysis. EJNMMI Res 14:36. https:\/\/doi.org\/10.1186\/S13550-024-01097-3","journal-title":"EJNMMI Res"},{"key":"5068_CR48","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.2967\/JNUMED.120.258574","volume":"62","author":"M Wondergem","year":"2021","unstructured":"Wondergem M, van der Zant FM, Broos WAM, Knol RJJ (2021) Matched-Pair Comparison of 18F-DCFPyL PET\/CT and 18F-PSMA-1007 PET\/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions. Journal of Nuclear Medicine 62:1422\u20131429. https:\/\/doi.org\/10.2967\/JNUMED.120.258574","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR49","doi-asserted-by":"publisher","unstructured":"Adnan A, Basu S (2023) PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications. Diagnostics 2023, Vol 13, Page 158 13:158. https:\/\/doi.org\/10.3390\/DIAGNOSTICS13010158","DOI":"10.3390\/DIAGNOSTICS13010158"},{"key":"5068_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/S12880-025-01557-9\/TABLES\/6","volume":"25","author":"L Ma","year":"2025","unstructured":"Ma L, Hao Y, Zhai L, et al (2025) Which PSMA PET\/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study. BMC Med Imaging 25:23. https:\/\/doi.org\/10.1186\/S12880-025-01557-9\/TABLES\/6","journal-title":"BMC Med Imaging"},{"key":"5068_CR51","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.2967\/JNUMED.124.267899","volume":"65","author":"IC Mainta","year":"2024","unstructured":"Mainta IC, Neroladaki A, Wolf NB, et al (2024) [68Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria. Journal of Nuclear Medicine 65:1376\u20131382. https:\/\/doi.org\/10.2967\/JNUMED.124.267899","journal-title":"Journal of Nuclear Medicine"},{"key":"5068_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13550-020-00745-8\/FIGURES\/3","volume":"11","author":"J Kuten","year":"2021","unstructured":"Kuten J, Dekalo S, Mintz I, et al (2021) The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. EJNMMI Res 11:1\u20138. https:\/\/doi.org\/10.1186\/S13550-020-00745-8\/FIGURES\/3","journal-title":"EJNMMI Res"},{"key":"5068_CR53","doi-asserted-by":"publisher","unstructured":"Mihatsch PW, Beissert M, Pomper MG, et al (2022) Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET\/CT. Cancers 2022, Vol 14, Page 270 14:270. https:\/\/doi.org\/10.3390\/CANCERS14020270","DOI":"10.3390\/CANCERS14020270"},{"key":"5068_CR54","doi-asserted-by":"publisher","first-page":"1368093","DOI":"10.3389\/FMED.2024.1368093\/BIBTEX","volume":"11","author":"M Mendoza-\u00c1vila","year":"2024","unstructured":"Mendoza-\u00c1vila M, Esparza-P\u00e9rez H, Castillo-L\u00f3pez JA, Rodea-Montero ER (2024) Agreement between PSMA-RADS and E-PSMA systems in classifying [18F]PSMA-1007 PET\/CT lesions among prostate cancer patients: exploring the correlation between lesion size and uptake. Front Med (Lausanne) 11:1368093. https:\/\/doi.org\/10.3389\/FMED.2024.1368093\/BIBTEX","journal-title":"Front Med (Lausanne)"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-05068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-025-05068-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-05068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:03:55Z","timestamp":1769148235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-025-05068-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["5068"],"URL":"https:\/\/doi.org\/10.1007\/s00261-025-05068-7","relation":{"references":[{"id-type":"doi","id":"10.1016\/J.EURURO.2023.06.008","asserted-by":"subject"},{"id-type":"doi","id":"10.1148\/RYCAN.240390\/ASSET\/IMAGES\/LARGE\/RYCAN.240390.FIG4.JPEG","asserted-by":"subject"}]},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}